ABP688
DrugCarbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
NCT Number: NCT01528241
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
Looking for future studies?
Notify Me55 year–80 year
All sexes
Interventional
Phase 1
Novartis Investigative Site, New York, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
At screening:
Specific to Major depression disorder (MDD)
Patients had to show following level of symptomatology:
Exclusion criteria
Specific criteria for healthy volunteers:
Specific criteria for MDD patients:
Criteria for both:
Other protocol-defined inclusion/exclusion criteria may apply.
Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Time frame: Day 1
Binding of [11C]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Time frame: Day 1, up to 60 minutes
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of [11C] ABP688. Specific times are recorded at the clinical site.
Time frame: Day 1
Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients.
Novartis Pharmaceuticals
Industry
A Multi-center, Open-label Study in Elderly Healthy Volunteers and Elderly Patients With Major Depressive Disorder to Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00044174
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT05321628
Anxiety Disorders, Behavior
Stockholm, Huddinge, Sweden
View Trial DetailsNCT06993662
Anxiety, Anxiety Disorders
Athens, Greece
View Trial DetailsNCT03851380
Behavior, Behavioral Symptoms
Palo Alto, California, United States
View Trial Details